DATAR CANCER GENETICS
Company Snapshot
Company Overview
Datar Cancer Genetics is developing and marketing genetic testing services. Services include encyclopedic tumor analysis (Exacta), and liquid biopsy testing for brain tumors and other applications.
Datar’s lead liquid biopsy test, Gliotrack, detects ctDNA, mRNA and microRNA released by the tumor cells in patients with glioma.
The company’s liquid biopsy tests include diagnosis (TruBlood), treatment guidance (Exacta, celldx, chemo-scale) and monitoring (CancerTrack).
TruBlood uses CTC and cfDNA analysis for patients who are symptomatic or where invasive biopsy had been inconclusive.
Exacts (Encyclopedic Tumor Analysis) is designed for patients with drug-resistant cancers who have failed one or more line of treatment.
CellDx is a tissue-based test for patients diagnosed with cancer and who need molecular profiling of the tumor to determine appropriate therapies.
ChemoScale analyzes CTCs to evaluate response or resistance to chemotherapy drugs.
CancerTrack analyzes ctDNA to monitor response to therapy and recurrence of cancer.
Company's Business Segments
- Molecular Oncology : Molecular Oncology Facility with a Fully Equipped Laboratory, Integrated Process Platforms, an In-House Bioinformatics Team for the Early Detection ff Cancer, Personalized Therapy.
Applications/End User Industries
- Oncology
- Biotechnology
- Healthcare
- Pharmeceutical
- Cancer Research
- Personalized Therapy
- Bioinformatics
- Cancer Genetics
- Molecular Genetics
- Liquid Biopsy
